All In Biotech

Drug Trial Radar · NCT06945458

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

A Phase 1b Open-label, Multicenter, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered KT-621 in Adult Participants With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Apr 17, 2025

Primary completion

Nov 10, 2025

Study completion Nov 10, 2025

Sponsor

Lead sponsor
Kymera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • KT-621Drug

    Oral drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: From enrollment through the safety follow-up visit on Day 43
  2. Incidence of treatment-emergent potentially clinically-significant abnormalities in electrocardiogram (ECG) results, vital signs, or laboratory test results from the serum chemistry, hematology (with differential), chemistry, or coagulation panels.Time frame: From enrollment through the safety follow-up visit on Day 43

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Kymera Investigative Site

    Birmingham, Alabama

  • Kymera Investigative Site

    Fountain Valley, California

  • Kymera Investigative Site

    Santa Monica, California

  • Kymera Investigative Site

    Boynton Beach, Florida

  • Kymera Investigative Site

    Hollywood, Florida

  • Kymera Investigative Site

    Tampa, Florida

  • Kymera Investigative Site

    Fargo, North Dakota

  • Kymera Investigative Site

    Dublin, Ohio

  • Kymera Investigative Site

    Springfield, Ohio

  • Kymera Investigative Site

    Tulsa, Oklahoma

  • Kymera Investigative Site

    Charleston, South Carolina

  • Kymera Investigative Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.